

Date: March 12, 2025

To, Sr. General Manager Listing Department **BSE Limited** Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400001 To, Sr. General Manager Listing Department **National Stock Exchange of India Limited** Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051

BSE Scrip Code: 544319

**NSE Symbol: SENORES** 

Dear Sir/Madam,

Subject: Additional disclosure in respect of our intimation dated March 11, 2025, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Further to our intimation dated March 11, 2025, regarding acquisition of 8454 equity shares from certain shareholders (Public Category) of Havix Group Inc. D/B/A Aavis Pharmaceuticals ("Havix" or "the Target Company") aggregating to 3.73% of the total paid up share capital of Havix, we would like to apprise the stakeholders that post acquisition of the said shares, the direct shareholding of the Company in Havix will increase from 51.23% to 54.96% and the aggregate shareholding of the Company (along with the shareholding of its wholly owned subsidiary – Senores Pharmaceuticals, Inc.) in Havix will increase from 66.58% to 70.31%.

Further, in Annexure-1 to our aforesaid intimation dated March 11, 2025, the indicative time-period for completion of the said acquisition be read as "45 days" instead of "10 days". The stakeholders are requested to take note of the same.

This is for information and records.

Thank you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra Company Secretary and Compliance Officer ICSI Membership No.: F11464

## **Senores Pharmaceuticals Limited**

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: <u>info@senorespharma.com</u> W: www.senorespharma.com | CIN No.: U24290GJ2017PLC100263